Chemotherapy approaches to melanoma

Dermatologic Clinics

Volumn 20, Issue 4, 2002, Pages 709-712

  Pavlick, Anna C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; DOCETAXEL; LOMUSTINE; MITOZOLOMIDE; PACLITAXEL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY; LIMB PERFUSION; MELANOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; MALE; MELANOMA; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036788412     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00033-5     Document Type: Review

References (23)

1. Balch C, Buzaid A, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
2. Anderson C, Buzaid A, Legha S. Systemic treatment for advanced cutaneous melanoma. Oncology 1995; 9:1149-54.
3. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea, Fotemustine, in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasis. Cancer 1990;66:1872-3.
4. Einzig A, Hochster H, Wiernik P, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991;9:59-63.
5. Bedikian A, Weiss G, Legha S, et al. Phase II trial of docetaxel in patients with advanced cutaneous melanoma previously untreated with chemotherapy. J Clin Oncol 1995;13:2895-8.
6. DelPrete S, Maurer L, O'Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, DTIC and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-7.
7. Buzaid A, Murren J, Durerage H. High-dose cisplatin with DTIC and tamoxifen in the treatment of metastatic melanoma. Cancer 1991;68:1238-41.
8. Flaherty L, Liu P, Daniels D, et al. The addition of tamoxifen to DTIC and cisplatin in a SWOG phase II trial in metastatic malignant melanoma Stage IV. Proc Am Soc Clin Oncol 1993;12:394.
9. Morton R, Creagen E, Schaid D, et al. Phase II trial of recombinant leukocyte A interferon (IFN-alpha-2a) plus 1,3-bis (2-chloroethyl)-1-nitrosurea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma. Am J Clin Oncol 1991;14:152-6.
10. Flaherty L, Liu P, Fletcher W, et al. DTIC and out-patient II-2 in the treatment of metastatic malignant melanoma: a phase II SWOG trial. J Natl Cancer Inst 1992;84:893-8.
11. Atkins M, O'Boyle K, Sosman J, et al. Multi-institutional phase II trial of intensive chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12: 1553-60.
12. Legha S, Renz S, Plager C, et al. Biochemotherapy using II-2 and IFN in combination with cisplatin, vinblastine and DTIC in advanced melanoma. Proceedings of the American Society of Clinical Oncology 1991;10:293.
13. Legha S, Renz S, Bedekian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and DTIC (CVD) and biochemotherapy using II-2 and IFN. Ann Oncol 1996;7:827-33.
14. Legha S, Buzaid A, Bedekain A, et al. Efficacy of concurrent biochemotherapy using II-2 and IFN and chemotherapy with cisplatin, vinblastine and DTIC in metastatic melanoma. Proceedings of the American Association of Clinical Research 1994;35:87.
15. Comis RL. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Res 1976;64:1123-7.
16. Buzaid A, Legha S, Winn R, et al. Cisplatin, vinblastine and dacarbazine versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial. Proc Am Soc Clin Oncol 1993;12:389.
17. Berd D, Mastrangelo M. Combination chemotherapy of metastatic melanoma. J Clin Oncol 1995;13:796-7.
18. Kirkwood J, Ernstroff M, Giuliano A, et al. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst 1990;82:1062-70.
19. Dorval T, Negrier S, Chevreau C, et al. Results of a French multicentric randomized trial of chemoimmunotherapy (cisplatin, IL-2, with or without IFN) in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1994;13:395.
20. Franker DL. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Houghton AN, Sober AJ, Soong S, editors. Cutaneous melanoma. St. Louis, MI: Quality Medical Publishing Inc; 1998. p. 281-300.
21. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced melanoma. J Clin Oncol 2000;18:158-66.
22. Hwu W, Panageas K, Krown S, et al. Phase I study of temozolomide and thalidomide in the treatment of metastatic melanoma. Proc Am Soc Clin Oncol 2001; 20:1424.
23. Jansen B, et al. Systemic treatment with bcl-2 antisense down-regulates tumor content of bcl-2 protein and induces major antitumor responses in patients with melanoma when combined with dacarbazine [abstract]. In: Proceedings of the Annual Meeting of the American Association of Cancer Research 2000;41:23.